Jenny MacLennan

About me
Trained in Medicine at Oxford and Cambridge.

Research interests
Bacterial carriage studies and vaccination.



(To insert a photo, click the “Add Media” button above, then choose the “Upload Media” tab.)

1.    MacLennan, J., Obaro, S., Deeks, J., Williams, D., Pais, L., Carlone, G., Moxon, R. & Greenwood, B. (1999). Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine  17, 3086-3093.
2.    MacLennan, J. M., Shackley, F., Heath, P. T. et al. (2000). Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. Jama  283, 2795-2801.
3.    MacLennan, J. M., Urwin, R., Obaro, S., Griffiths, D., Greenwood, B. & Maiden, M. C. (2000). Carriage of serogroup W-135, ET-37 meningococci in The Gambia: implications for immunisation policy? Lancet  356, 1078.
4.    Nurkka, A., MacLennan, J., Jantti, V., Obaro, S., Greenwood, B. & Kayhty, H. (2000). Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated gambian children. Vaccine  19, 547-556.
5.    English, M., MacLennan, J. M., Bowen-Morris, J. M. et al. (2001). A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine  19, 1232-1238.
6.    MacLennan, J. (2001). Meningococcal group C conjugate vaccines. Arch Dis Child  84, 383-386.
7.    Joseph, H., Ryall, R., Bybel, M., Papa, T., MacLennan, J., Buttery, J. & Borrow, R. (2003). Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J Infect Dis  187, 1142-1146.
8.    McVernon, J., MacLennan, J., Pollard, A. J., Oster, P., Wakefield, M. J., Danzig, L. & Moxon, E. R. (2003). Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatric Infectious Disease Journal  22, 659-661.
9.    MacLennan, J., Kafatos, G., Neal, K. et al. (2006). Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis  12, 950-957.
10.    Maiden, M. C., Ibarz-Pavon, A. B., Urwin, R. et al. (2008). Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity. J Infect Dis  197, 737-743.
11.    Snape, M. D., Maclennan, J. M., Lockhart, S., English, M., Yu, L. M., Moxon, R. E. & Pollard, A. J. (2009). Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine. Pediatr Infect Dis J  28, 92-97.
12.    Ibarz-Pavon, A. B., Maclennan, J., Andrews, N. J. et al. (2011). Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis  204, 1046-1053.
13.    Greenwood, B., Chiarot, E., MacLennan, C. A. & O’Ryan, M. (2012). Can we defeat meningococcal disease in low and middle income countries? Vaccine  30, Supplement 2, B63-B66.